Atea, riding interest in COVID-19 drugs, pulls off one of 2020's top biotech IPOs

Atea, riding interest in COVID-19 drugs, pulls off one of 2020's top biotech IPOs

Source: 
BioPharma Dive
snippet: 

Boston biotech Atea Pharmaceuticals, a developer of small molecule drugs for infectious diseases, has raised $300 million in an initial public offering, selling 12.5 million shares at $24 apiece.